Back

Outcomes of reduced-dose versus standard-dose apixaban in atrial fibrillation patients meeting dose-reduction criteria: a propensity score–matched analysis

29 August 2026 (11:15 - 11:45)
Organised by: Logo
Congress Presentation Part of: Managing and improving safety in antithrombotic pharmacotherapy Anticoagulants ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Ademola Ajibade

University of Iowa Hospitals and Clinics, Iowa City (United States of America)

3 More presentations in this session

Presentation thumbnail
Development and validation of a novel bleeding risk score during direct oral anticoagulant therapy in patients with cancer-associated venous thromboembolism
Doctor T. Nagai (Kyoto, JP)
Abstract Slides
Presentation thumbnail
Oral anticoagulation monotherapy versus dual antithrombotic therapy in chronic coronary syndrome patients requiring long-term anticoagulation: a bayesian meta-analysis of randomised controlled trials
Doctor B. Rodriguez-Tapia (Trujillo, PE)
Abstract Slides
Presentation thumbnail
Intraoperative antithrombotic drug removal during urgent CABG: early German experience with a novel hemoadsorption device
Professor U. Zeymer (Ludwigshafen, DE)
Abstract Slides

Access the full session

Session thumbnail
Managing and improving safety in antithrombotic pharmacotherapy

The Event

Event poster

ESC Congress 2026

29 August 2026 11:15 CET
You may be interested in
thumbnail
Congress Presentation
Reduced dose, but not reduced risk: rates of inappropriate apixaban dose reduction and stroke and bleeding incidence
27 August 2022
thumbnail
Congress Presentation
Direct oral anticoagulants versus left atrial appendage closure in elderly patients (>80) with atrial fibrillation: results from a propensity matched analysis in real-life patients
28 August 2020
thumbnail
Congress Presentation
Reduction of cardiovascular events in patients with cardiovascular disease with the CV-polypill: a retrospective and propensity score matching study
27 August 2021
thumbnail
Congress Presentation
Comparing Rivaroxaban and Apixaban in GARFIELD-AF according to ROCKET AF and ARISTOTLE trial selection criteria
27 August 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources